Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane A Plumb

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Methods in Molecular Medicine|November 25, 2003
Cell sensitivity assays: the MTT assayJane A Plumb
Methods in Molecular Medicine|November 25, 2003
Cell sensitivity assays: clonogenic assayJane A Plumb
Expert Review of Anticancer Therapy|July 24, 2004
Demethylation of DNA by decitabine in cancer chemotherapyRobert Brown, Jane A Plumb
Journal of Inorganic Biochemistry|March 6, 2014
A cisplatin slow-release hydrogel drug delivery system based on a formulation of the macrocycle cucurbit[7]uril, gelatin and polyvinyl alcoholRabbab Oun, Jane A Plumb, Nial J Wheate
Journal of Inorganic Biochemistry|August 20, 2013
DNA-based aptamer fails as a simultaneous cancer targeting agent and drug delivery vehicle for a phenanthroline-based platinum(II) complexNicola L McGinely, Jane A Plumb, Nial J Wheate
Journal of Ovarian Research|September 20, 2015
Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer modelNatividad Gomez-Roman, Fiona McGregor, Nial J Wheate, et al.
Journal of Inorganic Biochemistry|June 28, 2011
Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatinGordon J Kirkpatrick, Jane A Plumb, Oliver B Sutcliffe, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2007
A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitorsMirjam T Epping, Liming Wang, Jane A Plumb, et al.
Journal of Medicinal Chemistry|October 14, 2005
Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cellsKlaus Pors, Jane A Plumb, Robert Brown, et al.
Molecular Cancer Therapeutics|July 29, 2003
Alchemix: a novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancerKlaus Pors, Zennia Paniwnyk, Paul Teesdale-Spittle, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Methods in Molecular Medicine|November 25, 2003
Cell sensitivity assays: the MTT assayJane A Plumb
Methods in Molecular Medicine|November 25, 2003
Cell sensitivity assays: clonogenic assayJane A Plumb
Expert Review of Anticancer Therapy|July 24, 2004
Demethylation of DNA by decitabine in cancer chemotherapyRobert Brown, Jane A Plumb
Journal of Inorganic Biochemistry|March 6, 2014
A cisplatin slow-release hydrogel drug delivery system based on a formulation of the macrocycle cucurbit[7]uril, gelatin and polyvinyl alcoholRabbab Oun, Jane A Plumb, Nial J Wheate
Journal of Inorganic Biochemistry|August 20, 2013
DNA-based aptamer fails as a simultaneous cancer targeting agent and drug delivery vehicle for a phenanthroline-based platinum(II) complexNicola L McGinely, Jane A Plumb, Nial J Wheate
Journal of Ovarian Research|September 20, 2015
Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer modelNatividad Gomez-Roman, Fiona McGregor, Nial J Wheate, et al.
Journal of Inorganic Biochemistry|June 28, 2011
Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatinGordon J Kirkpatrick, Jane A Plumb, Oliver B Sutcliffe, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2007
A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitorsMirjam T Epping, Liming Wang, Jane A Plumb, et al.
Journal of Medicinal Chemistry|October 14, 2005
Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cellsKlaus Pors, Jane A Plumb, Robert Brown, et al.
Molecular Cancer Therapeutics|July 29, 2003
Alchemix: a novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancerKlaus Pors, Zennia Paniwnyk, Paul Teesdale-Spittle, et al.
Pageof 2